View Item 

Show simple item record

Influence of ejection fraction on cause‐specific mortality in heart failure with preserved ejection fraction
dc.contributor.authorBajaj, Navkaranbir S.
dc.contributor.authorClaggett, Brian
dc.contributor.authorLewis, Eldrin F.
dc.contributor.authorDesai, Akshay S.
dc.contributor.authorFang, James C.
dc.contributor.authorO’Meara, Eileen
dc.contributor.authorShah, Sanjiv J.
dc.contributor.authorSweitzer, Nancy K.
dc.contributor.authorFleg, Jerome L.
dc.contributor.authorPitt, Bertram
dc.contributor.authorRouleau, Jean L.
dc.contributor.authorFinn, Peter
dc.contributor.authorPfeffer, Marc A.
dc.contributor.authorSolomon, Scott D.
dc.date.accessioned2018-05-15T20:14:27Z
dc.date.available2019-06-03T15:24:19Zen
dc.date.issued2018-04
dc.identifier.citationBajaj, Navkaranbir S.; Claggett, Brian; Lewis, Eldrin F.; Desai, Akshay S.; Fang, James C.; O’Meara, Eileen; Shah, Sanjiv J.; Sweitzer, Nancy K.; Fleg, Jerome L.; Pitt, Bertram; Rouleau, Jean L.; Finn, Peter; Pfeffer, Marc A.; Solomon, Scott D. (2018). "Influence of ejection fraction on cause‐specific mortality in heart failure with preserved ejection fraction." European Journal of Heart Failure 20(4): 815-816.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/143697
dc.publisherJohn Wiley & Sons, Ltd
dc.titleInfluence of ejection fraction on cause‐specific mortality in heart failure with preserved ejection fraction
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/143697/1/ejhf1040.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/143697/2/ejhf1040_am.pdf
dc.identifier.doi10.1002/ejhf.1040
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceButler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O’Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail 2014; 2: 97 – 112.
dc.identifier.citedreferenceSolomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112: 3738 – 3744.
dc.identifier.citedreferencede Denus S, O’Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras M, Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL. Spironolactone metabolites in TOPCAT ‐ new insights into regional variation. N Engl J Med 2017; 376: 1690 – 1692.
dc.identifier.citedreferencePfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34 – 42.
dc.identifier.citedreferenceDesai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O’Meara E, Shaburishvili T, Pitt B, Pfeffer MA. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011; 162: 966 – 972.e10.
dc.identifier.citedreferencePitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383 – 1392.
dc.identifier.citedreferenceSolomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O’Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016; 37: 455 – 462.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf1040.pdf
Size:
982.1KB
Format:
PDF
View/Open
Name:
ejhf1040_am.pdf
Size:
227.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.